投资者

/投资者
投资者 2018-05-30T18:41:16+00:00

Oramed Pharmaceuticals Inc.
(ORMP) – NasdaqCM

3.99
-0.03 (-0.75%)
Refresh Quote
Exchange :NASDAQ (US Dollar)
Ric Code :ORMP
Volume :40,743
Date :12-13-2018

* Minimum 20 minute delay See terms

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, can better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles… [READ MORE >]

Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study

十一月 13th, 2018|Oramed Completes Over 50% Randomization in Its Pivotal 90-Day Clinical Study已关闭评论

NEW YORK, Nov. 13, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has successfully randomized more [...]

Oramed to Present at the Tides Europe 2018 Conference

十一月 5th, 2018|Oramed to Present at the Tides Europe 2018 Conference已关闭评论

NEW YORK, Nov. 5, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com),  a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate [...]

Oramed to Present at Cardiometabolic Health Congress

十月 23rd, 2018|Oramed to Present at Cardiometabolic Health Congress已关闭评论

NEW YORK, Oct. 23, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that a scientific abstract summarizing two [...]

Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH

十月 4th, 2018|Oramed Enrolls First Patient in Its Clinical Study for Oral Insulin in the Treatment of NASH已关闭评论

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has enrolled the first [...]